RLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
RLC Labs Inc. is recalling Nature-Throid tablets nationwide because they were manufactured under conditions found to be subpotent.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the source explicitly states the product was manufactured under conditions found to be subpotent, which aligns with the rubric criteria for Severe severity.
Plain-English summary
RLC Labs Inc. is recalling Nature-Throid, Thyroid USP tablets (3/4 Grain) in 30, 60, 90, 100, and 1,000-count bottles. The recall covers all lots with expiration dates between October 2020 and July 2023. The product is distributed nationwide in the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The source text states that the affected tablets were manufactured under the same conditions as those found to be subpotent.
Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Nature-Throid, Thyroid USP [liothyronine (T3) 6.75 mcg and levothyroxine (T4) 28.5 mcg], 3/4 Grain (48.75 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3302-4; b) 60-count bottles, NDC 64727-3302-5; c) 90-count bottles, NDC 64727-3302-6; d) 100-count bottles, NDC…
- Manufacturer
- RLC Labs Inc.
- Category
- Drug — Thyroid Hormone
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots with expiry between 10/2020-07/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 24 products in this recall →Related recalls
Same manufacturer · RLC Labs Inc.
See all →- SevereRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- SevereRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22
Similar recalls
- SeverePD-Rx Recalls Nature-Throid Tablets Due to CGMP Deviations and Sub-Potency Risk
FDA (Drugs) · 2020-10-14
- ModeratePreferred Pharmaceuticals Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-30
- ModeratePreferred Pharmaceuticals Recalls Nature-Throid Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2020-09-30
- ModerateLloyd Inc. Recalls Levothroid Tablets Due to cGMP Deviations
FDA (Drugs) · 2012-12-12
- HighLevothyroxine Sodium Tablets Recalled for Potency Variation and Dosage Failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18